NCT05572190View on ClinicalTrials.gov

Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

March 20, 2024

Study Completion Date

March 31, 2024

Conditions
Acute Pain
Interventions
DRUG

ETR028, ETR029, [ETR028 + ETR029] or HCBT

Hydrocodone prodrugs

Trial Locations (1)

45227

RECRUITING

Medpace, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

collaborator

Charles River Laboratories International Inc.

UNKNOWN

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

Ohio Third Frontier

OTHER

lead

Elysium Therapeutics, Inc.

INDUSTRY